<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">IJCM</journal-id><journal-title-group><journal-title>International Journal of Clinical Medicine</journal-title></journal-title-group><issn pub-type="epub">2158-284X</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.4236/ijcm.2022.1311038</article-id><article-id pub-id-type="publisher-id">IJCM-121441</article-id><article-categories><subj-group subj-group-type="heading"><subject>Articles</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>Medicine&amp;Healthcare</subject></subj-group></article-categories><title-group><article-title>
 
 
  Platelet-Derived Growth Factor-A Overexpression Correlates with Atrial Fibrosis in the Patients with Atrial Fibrillation Secondary to Rheumatic Valvular Disease
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Mengxia</surname><given-names>Su</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Rui</surname><given-names>Zhao</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Xu</surname><given-names>Wang</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Yulu</surname><given-names>Yang</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Feng</surname><given-names>Ma</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Junqiang</surname><given-names>Pan</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="corresp" rid="cor1"><sup>*</sup></xref></contrib></contrib-group><aff id="aff2"><addr-line>Medical College of Yan’an University, Yan’an, China</addr-line></aff><aff id="aff1"><addr-line>Department of Cardiology, Xi’an Central Hospital, Xi’an, China</addr-line></aff><pub-date pub-type="epub"><day>01</day><month>11</month><year>2022</year></pub-date><volume>13</volume><issue>11</issue><fpage>501</fpage><lpage>514</lpage><history><date date-type="received"><day>22,</day>	<month>October</month>	<year>2022</year></date><date date-type="rev-recd"><day>21,</day>	<month>November</month>	<year>2022</year>	</date><date date-type="accepted"><day>24,</day>	<month>November</month>	<year>2022</year></date></history><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  Objective: To investigate the relationship between platelet-derived growth factor-A (PDGF-A) and atrial fibrosis in patients who have developed atrial fibrillation (AF) secondary to rheumatic valvular disease. 
  Methods: 84 selected patients participated in the current study who have developed rheumatic heart disease and were going to have a cardiac surgical operation. In the current study, whole subjects were divided into two group, they were atrial fibrillation (AF) group (the quantity is thirty-nine) and sinus rhythm (SR) group (the quantity is forty-five). Before the operation, complete clinical data was available for the whole patients. During the operation, the right atrial tissue (0.3 - 0.5 mm
  <sup>3</sup>) was disserted from every patient. Right atrial fibrosis was observed by Masson staining and the distribution of PDGF-A in right atrium specimen was observed by immunohistochemistry. RT-PCR techniques were applied to admeasure the mRNA expressions of PDGF-A in patients’ atrial tissue. At the same time, western-Blot techniques were employed to admeasure the protein expressions of PDGF-A. 
  Results: In baseline clinical characteristics, in both AF group and SR group, there was no apparently difference between them (P &gt; 0.05); compared with SR group, the diameters of left atrium and right atrium in AF group were apparently increased (P &lt; 0.05). The results of Masson staining revealed that the atrial tissue fibrosis was clearer in AF group, and collagen volume fraction in the AF group was evidently exceeding SR group (P &lt; 0.05). The expressions of PDGF-A’s mRNA and protein from right atrial tissue in the AF group were evidently greater than SR group (P &lt; 0.05). The mRNA and protein expressions of PDGF-A and the right atrium diameter go hand in hand. 
  Conclusion: Atrial remodeling plays an important role in patients with valvular atrial fibrillation; PDGF-A in patients with AF was highly expressed in the right atrial, and was closely related with atrial fibrosis.
 
</p></abstract><kwd-group><kwd>Atrial Fibrillation</kwd><kwd> Platelet-Derived Growth Factor-A</kwd><kwd> Collagen Volume Fraction</kwd><kwd> Atrial Fibrosis</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>1. Introduction</title><p>The most common supraventricular arrhythmia in the world is Atrial fibrillation (AF), which is characterized by rapid and irregular activation of the atrium [<xref ref-type="bibr" rid="scirp.121441-ref1">1</xref>] [<xref ref-type="bibr" rid="scirp.121441-ref2">2</xref>].</p><p>Several cardiovascular disorders predispose to AF, such as valvular heart disease [<xref ref-type="bibr" rid="scirp.121441-ref3">3</xref>], coronary artery disease, congestive heart failure [<xref ref-type="bibr" rid="scirp.121441-ref4">4</xref>] [<xref ref-type="bibr" rid="scirp.121441-ref5">5</xref>], and hypertension. The most important histopathological change in atrial fibrillation is atrial fibrosis which involves a disproportionate excessive accumulation of extracellular matrix [<xref ref-type="bibr" rid="scirp.121441-ref6">6</xref>] between muscle fibers and around blood vessels. Atrial fibrosis underlies atrial structural remodeling [<xref ref-type="bibr" rid="scirp.121441-ref6">6</xref>] [<xref ref-type="bibr" rid="scirp.121441-ref7">7</xref>] and reportedly contributes to the development and maintenance of AF [<xref ref-type="bibr" rid="scirp.121441-ref8">8</xref>] [<xref ref-type="bibr" rid="scirp.121441-ref9">9</xref>]. Although, it is not clear for the precise pathophysiological mechanisms, it has been proposed that extracellular matrix-modulating enzymes, cytokines, growth factors, and components of the fibrinolytic system play considerable roles in AF.</p><p>Platelet-derived growth factor-A (PDGF-A), a member of the PDGF/vascular endothelial growth factor family [<xref ref-type="bibr" rid="scirp.121441-ref10">10</xref>], is highly expressed in the myocardium throughout development and adulthood [<xref ref-type="bibr" rid="scirp.121441-ref11">11</xref>]. PDGF-A solely binds to PDGF receptor-α (PDGFR-α), and subsequently activates several intracellular signaling cascades, then stimulates growth, differentiation and migration of cells [<xref ref-type="bibr" rid="scirp.121441-ref10">10</xref>] [<xref ref-type="bibr" rid="scirp.121441-ref12">12</xref>]. It is known that PDGF-A and PDGFR-α are essential for the development of support cells in the vasculature, and involved into tissue fibrosis. However, it is not well investigated whether they contribute to atrial fibrosis. In order to determine whether PDGF-A participates in atrial fibrosis associated with AF, we investigated the expression and distribution of PDGF-A in patients with and without AF.</p></sec><sec id="s2"><title>2. Materials and Methods</title><sec id="s2_1"><title>2.1. Patient Enrollment and Data Collecting</title><p>84 consecutive patients with rheumatic heart disease (RHD) who were going to undertake cardiac surgery were enrolled in this study at First Affiliated Hospital of Xi’an Jiaotong University, Xijing Hospital and Shanxi Provincial People’s Hospital in 2012. All patients consecutively underwent simple mitral valve replacement surgery.</p><p>Baseline demographics, physical examination, routine laboratory testing, echocardiography, and additional clinical data were available for all patients before surgery.</p><p>84 selected patients were divided into two group, they were atrial fibrillation (AF) group (the sample size is thirty-nine) and sinus rhythm (SR) group (the sample size is forty-five). The subjects were considered eligible to be enrolled into the AF group if they had obvious AF history and had been documented by electrocardiogram with AF for more than 6 months. The SR group is composed of patients who is sinus rhythm and without history of atrial fibrillation.</p><p>Before surgery, no patients received any type of angiotensin receptor blockers (ARB) or angiotensin-converting enzyme inhibitors (ACEI) for at least six months, and none of the subjects had taken anti-inflammatory drugs previously more than two weeks before the study. In the present study, we excluded the patients as follows: 1) patients who exceeded 65 years old or had a history of cancer; 2) patients with complicated diabetes, renal or liver failure; 3) patients with hyperthyroidism, hypertension, autoimmune disease; 4) patients with heart failure over New York Heart Association (NYHA) III or left ventricular ejection fraction (LVEF) less than 40%, and other heart diseases; 5) patients who suffered rheumatic fever in active stage.</p><p>Before they take part in this investigation, every selected patient has signed informed consent forms that obtained from every selected patient or their family members. All informed consent forms and the procedure protocols were authorized by the Ethics Committee of the First Affiliated Hospital of Xi’an Jiaotong University. The investigation tallies with the principles outlined in the Declaration of Helsinki.</p></sec><sec id="s2_2"><title>2.2. Human Cardiac Tissue Collection and Storage</title><p>All patients underwent cardiac surgical operation with moderate hypothermia (33˚C - 34˚C) and the right atrium (RAA) tissue (0.3 - 0.5 mm<sup>3</sup>) was disserted during the surgery. Each piece of tissue was cut immediately into three parts. One was dropped into liquid nitrogen and then stored in the –80˚C for RT-PCR and Western blot. Samples for immunofluorescence were promptly implanted into Tissue OCT-Freeze compound, flash frozen, and cut into 10-μm sections using Cryostat at optimal cutting temperature. All tissue sections were stored at –80˚C until they were used for immunostaining and analysis. The third was fixed in 4% paraformaldehyde solution for 12 - 24 hours, imbedded in paraffin with Masson’s trichrome staining.</p></sec><sec id="s2_3"><title>2.3. Masson’s Trichrome Staining and Collagen Volume Fraction Assay</title><p>The specimens fixed in 4% paraformaldehyde were subjected to alcoholic dehydration and embedded in paraffin. 4 μm serial sections were sliced and subjected to Masson’s trichrome staining to highlight collagen fibers. Collagen volume fraction (CVF) assay was performed in tissue sections of the right atrium. Masson’s trichrome a was obtained from Boster Biological Engineering Corporation (Wuhan, China). Two slides of each sample were randomly selected and observed under polarization microscope. Six different vessel-free fields (&#215;200) of each slide were captured, and the images were analyzed using Image Pro Plus 6.0 (IPP 6.0) software. Collagen volume fraction was showed as the percentage of area of positive collagen staining in the total area of the image. The following formula was used to calculate the fibrosis score: collagen fiber area/total view area &#215; 100%.</p></sec><sec id="s2_4"><title>2.4. Detection of Positive for PDGF-A by Immunofluorescence Staining</title><p>The right atrial tissue samples were fixed in 4 per centum paraformaldehyde for 24 hour, afterwards in 30 per centum sucrose at 4˚C, until these tissues sank. After embedded in embedding reagent for frozen sections, 6-μm sections were obtained onto polylysine-coated slides. These slides were treated with acetone at 4˚C for 15 min and then with PBS (phosphate buffered solution). After treatment with 0.5% Triton X-100 at 37˚C for 30 minute, sections were hatched with 10% normal goat serum for 45minute at 37˚C. Subsequently, these sections were treated with foremost antibody (PDGF-A: 1:200; vimentin: 1:2500) at 4˚C overnight and secondary antibody (FITC conjugated goat anti-mouse antibody: 1:200; rhodamine red conjugated goat anti-rabbit antibody: 1:200; DAPI: 1:2000) at 37˚C for 30 min. After washing in PBS 5 times (5 min for each), mounting was done with anti-quencher, and sections were observed under a fluorescence microscope and photographed (&#215;200). ImageJ image analysis software was employed to analyze and merge these photographs. Negative controls were obtained by omitting the incubation with primary antibodies.</p></sec><sec id="s2_5"><title>2.5. Detection the Expressions of mRNA of PDGF-A and Type I, III Collagen by RT PCR</title><p>In brief, frozen human right atrial tissue samples were thawed and homogenized on ice, then overall RNA was isolated using RNA-simple Total RNA Kit (Tiangen Biotechnology, China) according to the corporation’s directions and quantified. Then, using ReverTra Ace qPCR RT Kit (Tiangen Biotechnology) and according to the manufacturer’s instructions, RNA was reversely transcribed into cDNA successfully. Amplification of cDNA was done on thermal cycler (Applied Biosystems Step One Plus System). The volume of the reaction mixture was 20 μl, according to merchant description, amplification was executed successfully (SYBR<sup>&#174;</sup> Premix Ex Taq<sup>TM</sup> II PCR kit and Applied Biosystems Step One Plus System). The reaction conditions are as follows: pre-denaturation for 30 second at 95˚C and 40 cycles of 95˚Cfor 5 second and 60˚C for 30 second. The melt curve was applied to define the specificity of products. The supporting software was applied to analysis the Ct value of products. According to the following formula: ΔCt = Cttarget gene − Ctinternal reference, the ΔCt was <xref ref-type="table" rid="table1">Table 1</xref> Oligonucleotide probes calculated in two groups, respectively. The relationship between the CT value of the target gene and the copies of this gene is negative, consequently, with the increase of the ΔCt, the gene expression decreased. Then, 2<sup>−ΔΔCt</sup> method was applied to calculate the relative mRNA expression of target genes. Oligonucleotide probes were in <xref ref-type="table" rid="table1">Table 1</xref>.</p></sec><sec id="s2_6"><title>2.6. Western Blotting Analysis</title><p>For Western blot analysis, frozen human right atrial tissue samples were used for protein isolation. Protein extraction was followed by the instruction of the total protein extraction kit (Apply gen Technologies Inc, China). Proteins (10 &#181;g) was isolated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and transferred to nitrocellulose membranes (Stratagene, USA) followed by staining with Ponceau S solution (Sigma, USA). The membranes were blocked with 5% non-fat dry milk and then explored rabbit polyclonal anti-human PDEGF-A (Abcam, USA) antibodies. Horse radish peroxidase-conjugated rabbit anti-mouse or anti-rabbit IgG (1:5000, Santa Cruz Biotechnology) was used as secondary anti-body followed by incubation with ECL Western Blot Detection Kit (Amersham, The Netherlands). The amount of protein chosen was in the linear immunoreactive signal range. The immunoreactive signals were exposed to Kodak film for 5 min and analyzed with gelpro analyzer after analysis software (Bio-Rad, USA) normalized by the corresponding value of β-actin. Experiments were repeated three times and the mean was scored.</p></sec><sec id="s2_7"><title>2.7. Statistical Analysis</title><p>All statistical analysis was made by the SPSS version 15.0. If they were normally distributed, continuous variables were indicated as mean &#177; standard deviation (x &#177; s). Comparisons of means were applied to independent t test between AF group and SR group. Groups for categorical variables were analyzed by chi-square. Correlation coefficients were assessed between PDGF-A and LAD, including the protein and mRNA expression of PDGF-A. A value of P &lt; 0.05 was considered statistically significant.</p><p>The reporting of this study conforms to STROBE guidelines.</p><table-wrap id="table1" ><label><xref ref-type="table" rid="table1">Table 1</xref></label><caption><title> Oligonucleotide probes</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >The target genes</th><th align="center" valign="middle" >Primers</th><th align="center" valign="middle" >Base composition</th></tr></thead><tr><td align="center" valign="middle"  rowspan="2"  >PDEGF-A</td><td align="center" valign="middle" >sense</td><td align="center" valign="middle" >5’-ACGTCCGCCAACTTCCTGA T-3’</td></tr><tr><td align="center" valign="middle" >antisense</td><td align="center" valign="middle" >5’-TCCGGATTCAGGCTTGTGGT-3’</td></tr><tr><td align="center" valign="middle"  rowspan="2"  >Type I collagen</td><td align="center" valign="middle" >sense</td><td align="center" valign="middle" >5’-GCGACAGAGGCATAAAGGGT-3’</td></tr><tr><td align="center" valign="middle" >antisense</td><td align="center" valign="middle" >5’-CCAGGGAGACCGTTGAGTC-3’</td></tr><tr><td align="center" valign="middle"  rowspan="2"  >Type III collagen</td><td align="center" valign="middle" >sense</td><td align="center" valign="middle" >5’-GAGCTTCCCAGAACATCA-3’</td></tr><tr><td align="center" valign="middle" >antisense</td><td align="center" valign="middle" >5’-ATTCCCCAGTGTGTTTCG-3’</td></tr><tr><td align="center" valign="middle"  rowspan="2"  >GAPDH</td><td align="center" valign="middle" >sense</td><td align="center" valign="middle" >5’-CCTCCTGCACCACCAACT-3’</td></tr><tr><td align="center" valign="middle" >antisense</td><td align="center" valign="middle" >5’-CTTCTGGGTGGCAGTGATG-3’</td></tr></tbody></table></table-wrap></sec></sec><sec id="s3"><title>3. Results</title><sec id="s3_1"><title>3.1. Clinical Characteristics</title><p>Patients’ characteristics are shown in <xref ref-type="table" rid="table2">Table 2</xref>. As a whole, most characteristics were similar between two groups. Left and right atrial diameters, measured by echocardiography, were significantly larger in the AF group than the SR group. All drugs were stopped at least 12 h before surgery.</p></sec><sec id="s3_2"><title>3.2. Collagen Content and Distribution</title><p>Representative examples of right atrial tissue stained with Masson’s trichrome from each group are shown in <xref ref-type="fig" rid="fig1">Figure 1</xref>. Although the marked interstitial alterations were present because of all patients with RMVD, an apparent difference was observed between the two groups.</p><p>Comparison with the SR (<xref ref-type="fig" rid="fig1">Figure 1</xref>(a)) patients, there were abundant collagen fibers in the AF (<xref ref-type="fig" rid="fig1">Figure 1</xref>(b)) group. On the contrary, only a small amount of collagen fibers was observed in the SR group. The CVF in the AF patients (45.4% &#177; 2.33%) increased more drastically than that in the SR patients (12.9% &#177; 1.02%) (P &lt; 0.001; <xref ref-type="fig" rid="fig1">Figure 1</xref>(c)), indicating some relationships between AF and fibrosis.</p><table-wrap id="table2" ><label><xref ref-type="table" rid="table2">Table 2</xref></label><caption><title> Clinical characteristics</title></caption><table><tbody><thead><tr><th align="center" valign="middle" ></th><th align="center" valign="middle" >AF (n = 39)</th><th align="center" valign="middle" >SR (n = 45)</th><th align="center" valign="middle" >t/χ<sup>2</sup> values</th><th align="center" valign="middle" >P value</th></tr></thead><tr><td align="center" valign="middle" >Basic data</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Age (years)</td><td align="center" valign="middle" >51.1 &#177; 9.0</td><td align="center" valign="middle" >48.1 &#177; 10.9</td><td align="center" valign="middle" >−1.405</td><td align="center" valign="middle" >0.164</td></tr><tr><td align="center" valign="middle" >Sex</td><td align="center" valign="middle" >24/15</td><td align="center" valign="middle" >19/26</td><td align="center" valign="middle" >3.083</td><td align="center" valign="middle" >0.086</td></tr><tr><td align="center" valign="middle" >male/female (n)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >SBP (mmHg)</td><td align="center" valign="middle" >112.4 &#177; 10.4</td><td align="center" valign="middle" >115.8 &#177; 14.3</td><td align="center" valign="middle" >1.242</td><td align="center" valign="middle" >0.218</td></tr><tr><td align="center" valign="middle" >DBP (mmHg)</td><td align="center" valign="middle" >71.7 &#177; 7.4</td><td align="center" valign="middle" >70.5 &#177; 11.5</td><td align="center" valign="middle" >−0.567</td><td align="center" valign="middle" >0.572</td></tr><tr><td align="center" valign="middle" >Laboratory examinations</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >WBC (10<sup>9</sup>/l)</td><td align="center" valign="middle" >6.29 &#177; 1.55</td><td align="center" valign="middle" >6.0 &#177; 1.91</td><td align="center" valign="middle" >−0.763</td><td align="center" valign="middle" >0.448</td></tr><tr><td align="center" valign="middle" >RBC (10<sup>12</sup>/l)</td><td align="center" valign="middle" >4.55 &#177; 0.67</td><td align="center" valign="middle" >4.44 &#177; 0.51</td><td align="center" valign="middle" >−0.811</td><td align="center" valign="middle" >0.420</td></tr><tr><td align="center" valign="middle" >HB (g/l)</td><td align="center" valign="middle" >137.1 &#177; 16.6</td><td align="center" valign="middle" >135.3 &#177; 16.8</td><td align="center" valign="middle" >−0.482</td><td align="center" valign="middle" >0.631</td></tr><tr><td align="center" valign="middle" >CR (&#181;mol/l)</td><td align="center" valign="middle" >92.47 &#177; 12.46</td><td align="center" valign="middle" >91.58 &#177; 12.43</td><td align="center" valign="middle" >−0.225</td><td align="center" valign="middle" >0.823</td></tr><tr><td align="center" valign="middle" >Echocardiograp hic parameters</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >LVEF (%)</td><td align="center" valign="middle" >53.10 &#177; 5.90</td><td align="center" valign="middle" >54.47 &#177; 5.90</td><td align="center" valign="middle" >1.041</td><td align="center" valign="middle" >0.301</td></tr><tr><td align="center" valign="middle" >LAD (mm)</td><td align="center" valign="middle" >58.03 &#177; 13.93*</td><td align="center" valign="middle" >49.55 &#177; 17.17*</td><td align="center" valign="middle" >−2.420</td><td align="center" valign="middle" >0.018</td></tr><tr><td align="center" valign="middle" >RAD (mm)</td><td align="center" valign="middle" >26.88 &#177; 4.81*</td><td align="center" valign="middle" >24.32 &#177; 4.26*</td><td align="center" valign="middle" >1.721</td><td align="center" valign="middle" >0.038</td></tr></tbody></table></table-wrap><p>SBP, systolic blood pressure; DBP, diastolic blood pressure; WBC, white blood cell; RBC, red blood cell; HB, hemoglobin; CR, serum creatinine; LVEF, left ventricular ejection fraction; LAD, left atrium diameter; RAD, right atrium diameter.</p></sec><sec id="s3_3"><title>3.3. mRNA Expressions of Type I Collagen and Type III Collagen</title><p>We performed qRT-PCR to test whether the type I collagen or type III collagen level increases in the AF patient’s right atrial tissues. After RT-PCR, the Ct value and number of cycles were applied to depiction, and finally, the mRNA’s amplification curve was acquired. The results demonstrated that the way has good repeatability and consistent amplification efficiency. 2<sup>−ΔΔCt</sup> method was applied to represent the relative expressions of target genes. The results displayed that the expression of mRNA of type I collagen was 2.042 &#177; 0.177 in the AF group, which was markedly higher than those in the SR group (0.988 &#177; 0.099), P &lt; 0.05 (<xref ref-type="fig" rid="fig2">Figure 2</xref>(a)).</p><p>Compared with the SR group, the expression of type III collagen mRNA in the AF group was greater, but there was no marked difference between the AF group and SR group (1.228 &#177; 0.151 VS 1.067 &#177; 0.068, P &gt; 0.05), (<xref ref-type="fig" rid="fig2">Figure 2</xref>(b)).</p></sec><sec id="s3_4"><title>3.4. Increased PDGF-A Expression in the Right Atrial of Patients with AF</title><p>Representative sections of the immunofluorescent stained right atrial tissue from each group are shown in <xref ref-type="fig" rid="fig3">Figure 3</xref>. Although PDGF-A was expressed in both groups, compared with the SR group, the level of the PDGF-A’s protein was apparently higher in the right atrial myocardium of the AF group (<xref ref-type="fig" rid="fig4">Figure 4</xref>).</p></sec><sec id="s3_5"><title>3.5. mRNA and Protein Expressions of PDGF-A</title><p>To test whether the PDGF-A increases in the right atrial tissues of the AF patients, we performed qRT-PCR and Western blotting. After real time PCR, the Ct value and number of cycles were applied to depiction, finally, the amplification curve of mRNA was acquired. The results demonstrated that the way has good repeatability and consistent amplification efficiency. 2<sup>−ΔΔCt</sup> method was applied to indicates the relative expressions of target genes. The results displayed that the PDGF-A’s mRNA expressions was 2.062 &#177; 0.184, the PDGF-A’s protein expressions was 1.282 &#177; 0.193 in AF group, which were markedly higher than those in SR group (0.991 &#177; 0.062 and 0.517 &#177; 0.067, respectively; P &lt; 0.01).</p></sec><sec id="s3_6"><title>3.6. Positive Correlation between Protein and Gene Expression of PDGF-A and Type I Collagen</title><p>A strong positive correlation existed between mRNA of PDGF-A and Type I collagen; western blotting revealed a strong positive correlation between protein of PDGF-A and mRNA of Type I collagen (<xref ref-type="fig" rid="fig5">Figure 5</xref>(a), r = 0.75; <xref ref-type="fig" rid="fig5">Figure 5</xref>(b), r = 0.72, respectively).</p></sec></sec><sec id="s4"><title>4. Discussion</title><p>Numerous studies demonstrate that patients with chronic AF secondary to RMVD are very common, and in these patients, structural remodeling is very</p><p>important for AF initiation and maintenance [<xref ref-type="bibr" rid="scirp.121441-ref13">13</xref>] [<xref ref-type="bibr" rid="scirp.121441-ref14">14</xref>]. Atrial fibrosis, as a hallmark of structural remodeling, has been implicated in tissue biopsies from AF patients [<xref ref-type="bibr" rid="scirp.121441-ref15">15</xref>]. Atrial fibrosis results from extracellularmatrix (ECM) accumulation of fibrillar collagen deposits [<xref ref-type="bibr" rid="scirp.121441-ref16">16</xref>]. Interstitial fibroblasts are differentiated to myo fibroblasts, which produce large amounts of collagen that replace degenerating myocardial cells. Expansion of ECM between cardiomyocytes may cause conduction delays and create alternate conduction pathways. These changes result in ectopicfoci and anisotropic conduction, creating nonuniform wave fronts that facilitate abnormal reentrant arrhythmias. Atrial fibrosis involves multiple factors such as the rennin-angiotensin system, TGFβ1, oxidative stress and in ﬂ ammation [<xref ref-type="bibr" rid="scirp.121441-ref17">17</xref>], but the exact mechanisms responsible for the structural changes that accompany AF in patients with RMVD are unknown. It is clear that atrial fibrosis occurs as a result of underlying cardiac disease (e.g. RMVD) affecting atrial tissue, and this process of remodeling in turn acts as a substrate for the initiation and maintenance of AF [<xref ref-type="bibr" rid="scirp.121441-ref18">18</xref>] [<xref ref-type="bibr" rid="scirp.121441-ref19">19</xref>].</p><p>Fibrosis is thought to occur on both a tissue and cellular level, and our study aimed to investigate the signaling pathways responsible for atrial fibrosis.</p><p>PDGF is mainly released by platelet α particles, in addition to monocytes, smooth muscle cells, endothelial cells, etc. can synthesize and release PDGF. PDGF is an important cell-stimulating agent that can stimulate the division and proliferation of a variety of cells, and has chemotaxis on fibroblasts and smooth muscle cells. About 85% of the extracellular matrix in normal myocardial tissue is composed of extracellular collagen secreted by fibroblasts, of which type I collagen accounts for about 85% and type III collagen accounts for about 11%.</p><p>PDGF-A is a potent growth factor that plays important roles in the proliferation [<xref ref-type="bibr" rid="scirp.121441-ref20">20</xref>], migration and survival of interstitial cells. An increasing number of proof has proved that PDGF/PDGFR signaling pathway is associated with the pathological fibrosis of multiple organs. PDGF and its receptor system play an important role in the development of myocardial fibrosis. In addition, during myocardial fibrosis in salt-sensitive hypertensive rats, PDGFR-α acts at early stage, and PDGFR-α expressions increase in fibroblasts and myofibroblasts, suggesting that PDGF/PDGFR signaling pathway is involved in the myocardial fibrosis via stimulating fibroblasts to proliferate and transform into myofibroblasts and to secret massive collagens [<xref ref-type="bibr" rid="scirp.121441-ref21">21</xref>] [<xref ref-type="bibr" rid="scirp.121441-ref22">22</xref>]. PDGF-α receptor mRNA is upregulated in acutely rejecting cardiac allografts, and mRNA of PDGF-A is upregulated in chronically rejecting cardiac allografts [<xref ref-type="bibr" rid="scirp.121441-ref23">23</xref>]. PDGF-A markedly increased pro fibrotic TGFβ-1 mRNA and accelerated the formation of myocardial fibrosis, indicating that PDGF may also increase TGFβ-1 levels to the formation of fibrosis. Atrial fibrillation, characterized by atrial fibrosis, is a frequent arrhythmia, which increases the risk of stroke and heart failure [<xref ref-type="bibr" rid="scirp.121441-ref24">24</xref>] [<xref ref-type="bibr" rid="scirp.121441-ref25">25</xref>]. Injection of neutralizing PDGFR-α specific antibody alleviated atrial fibrosis [<xref ref-type="bibr" rid="scirp.121441-ref26">26</xref>] [<xref ref-type="bibr" rid="scirp.121441-ref27">27</xref>]. The present research demonstrates that atrial fibrosis is distinct in patients with AF secondary to RMVD, establishing the relationship between PDGF-A and atrial fibrosis. This result strongly suggests that PGDF-A may be a good target for antifibrotic therapy in the heart.</p><p>But due to this study is a human tissue experiment, only right atrial tissue was collected, research data from left atrial tissue was missed. So it cannot simultaneously explore the relationship between PDGF-A and left atrial fibrosis in patients with atrial fibrillation secondary to RMVD, and therefore the distribution and expression of PDGF-A, the atrial structural remodeling cannot be contrasted between the left and right atria.</p></sec><sec id="s5"><title>5. Conclusion</title><p>There was significant atrial remodeling in patients with chronic AF secondary to RMVD26; PDGF-A in patients with atrial fibrillation was highly expressed in the right atrial, and was closely related to atrial fibrosis. PDGF-A may be up-regulated expression of type I collagen gene, which participated into atrial fibrosis. Present study is a human tissue experiment, only right atrial tissue is collected. So it cannot simultaneously explore the relationship between PDGF-A and left atrial fibrosis in patients with atrial fibrillation secondary to RMVD.</p></sec><sec id="s6"><title>Acknowledgements</title><p>The successful completion of this thesis is not alone, but the result of all the teachers who have guided me, helped my classmates and have always cared for and supported my family. I would like to express my deep gratitude to them.</p></sec><sec id="s7"><title>Funding Information</title><p>Financial supports from the Natural Science Foundation of Shaanxi Province, China (Grant No.: 2020JM-652), Fundamental Research Funds for the Central Universities of Xi’an Jiaotong University (Grant No.: xzy012020054), Cultivation Project of Xi’an Health Committee (Grant No.: 2020MS02) and Key Scientific Research Projects of inheritance and innovation of traditional Chinese medicine and development of “Qin medicine” (Grant No.: 2021-01-ZZ-013) are gratefully acknowledged.</p></sec><sec id="s8"><title>Conflicts of Interest</title><p>The authors declare no conflicts of interest regarding the publication of this paper.</p></sec><sec id="s9"><title>Cite this paper</title><p>Su, M.X., Zhao, R., Wang, X., Yang, Y.L., Ma, F. and Pan, J.Q. (2022) Platelet-Derived Growth Factor-A Overexpression Correlates with Atrial Fibrosis in the Patients with Atrial Fibrillation Secondary to Rheumatic Valvular Disease. International Journal of Clinical Medicine, 13, 501-514. https://doi.org/10.4236/ijcm.2022.1311038</p></sec></body><back><ref-list><title>References</title><ref id="scirp.121441-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Koniari, I., Artopoulou, E., Velissaris, D., et al. (2021) Biomarkers in the Clinical Management of Patients with Atrial Fibrillation and Heart Failure. Journal of Geriatric Cardiology, 18, 908-951.</mixed-citation></ref><ref id="scirp.121441-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Qi, M.M., Qian, L.L. and Wang, R.X. (2021) Modulation of SK Channels: Insight into Therapeutics of Atrial Fibrillation. Heart, Lung &amp; Circulation, 30, 1130-1139. https://doi.org/10.1016/j.hlc.2021.01.009</mixed-citation></ref><ref id="scirp.121441-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Haim, M., et al. (2015) Prospective National Study of the Prevalence, Incidence, Management and Outcome of a Large Contemporary Cohort of Patients with Incident Non-Valvular Atrial Fibrillation. Journal of the American Heart Association, 4, e001486. https://doi.org/10.1161/JAHA.114.001486</mixed-citation></ref><ref id="scirp.121441-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Goya, W.S., Olia, P., Lucy, L., et al. (2021) Adult Height and Incidence of Atrial Fibrillation and Heart Failure in Older Men: The British Regional Heart Study. IJC Heart &amp; Vasculature, 35, Article ID: 100835. https://doi.org/10.1016/j.ijcha.2021.100835</mixed-citation></ref><ref id="scirp.121441-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Zafrir, B., Lund, L.H., Laroche, C., et al. (2018) Prognostic Implications of Atrial Fibrillation in Heart Failure with Reduced, Mid-Range, and Preserved Ejection Fraction: A Report from 14964 Patients in the European Society of Cardiology Heart Failure Long-Term Registry. European Heart Journal, 39, 4277-4284. https://doi.org/10.1093/eurheartj/ehy626</mixed-citation></ref><ref id="scirp.121441-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Hiroko, I., Shigeru, M., Yoshiki, S. and Yoshiki, S. (2021) Cardiac Fibrosis Models Using Human Induced Pluripotent Stem Cell-Derived Cardiac Tissues Allow Anti-Fibrotic Drug Screening in Vitro. Stem Cell Research, 54, Article ID: 102420. https://doi.org/10.1016/j.scr.2021.102420</mixed-citation></ref><ref id="scirp.121441-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Zou, R., Zhang, D., Lv, L., et al. (2019) Bioinformatic Gene Analysis for Potential Biomarkers and Therapeutic Targets of Atrial Fibrillation-Related Stroke. Journal of Translational Medicine, 17, Article No. 45. https://doi.org/10.1186/s12967-019-1790-x</mixed-citation></ref><ref id="scirp.121441-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Li, Y.C., Zhang, R.J., Hu, N.W. and Li, N.S. (2021) Atrial Fibrosis Underlying Atrial Fibrillation (Review). International Journal of Molecular Medicine, 47, Article No. 9. https://doi.org/10.3892/ijmm.2020.4842</mixed-citation></ref><ref id="scirp.121441-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Koniari, I., Artopoulou, E., Velissaris, D., et al. (2021) Atrial Fibrillation in Patients with Systolic Heart Failure: Pathophysiology Mechanisms and Management. Journal of Geriatric Cardiology, 18, 376-397.</mixed-citation></ref><ref id="scirp.121441-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Li, N.N., Yin, Q. and Du, R.Z. (2021) Research Progress of Platelet Derived Growth Factor in Cardiovascular Diseases. Medical Review, 27, 3388-3393.</mixed-citation></ref><ref id="scirp.121441-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Michael, B. and Kristian, P. (2018) PDGF Family Function and Prognostic Value in Tumor Biology. Biochemical &amp; Biophysical Research Communications, 503, 984-990.</mixed-citation></ref><ref id="scirp.121441-ref12"><label>12</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Wang</surname><given-names> F.J. </given-names></name>,<etal>et al</etal>. (<year>2021</year>)<article-title>PDGFR α Progress of Its Role in Cardiac Development and Heart Disease</article-title><source> Journal of Practical Medicine</source><volume> 38</volume>,<fpage> 184</fpage>-<lpage>187+190</lpage>.<pub-id pub-id-type="doi"></pub-id></mixed-citation></ref><ref id="scirp.121441-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">Zhao, Q., Yang, W.T., Li, X.D. and Shan, Z.L. (2022) Research Progress on the Relationship between microRNA and Atrial Fibrillation and Atrial Fibrosis. Journal of PLA Medical College, 1-5.</mixed-citation></ref><ref id="scirp.121441-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">Lau, D.H., Schotten, U., et al. (2017) Pathophysiology of Paroxysmal and Persistent Atrial Fibrillation: Rotors, Foci and Fibrosis. Heart Lung &amp; Circulation, 26, 887-893. https://doi.org/10.1016/j.hlc.2017.05.119</mixed-citation></ref><ref id="scirp.121441-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">Ismail, A., Maciver, D.H., Garratt, C.J., et al. (2015) Effects of Persistent Atrial Fibrillation-Induced Electrical Remodeling on Atrial Electro-Mechanics—Insights from a 3d Model of the Human Atria. PLOS ONE, 10, e0142397. https://doi.org/10.1371/journal.pone.0142397</mixed-citation></ref><ref id="scirp.121441-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">Mariana, F.M., Isabel, M., Diana, M., et al. (2020) Atrial Matrix Remodeling in Atrial Fibrillation Patients with Aortic Stenosis. Revista portuguesa de cirurgia cardio-toracica e vascular: Orgao oficial da Sociedade Portuguesa de Cirurgia Cardio-Toracica e Vascular, 27, 250.</mixed-citation></ref><ref id="scirp.121441-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">Hu, J., Zhang, J.J., Li, L., et al. PU. 1 Inhibition Attenuates Atrial Fibrosis and Atrial Fibrillation Vulnerability Induced by Angiotensin-II by Reducing TGF-β1/Smads Pathway Activation. Journal of Cellular and Molecular Medicine, 25, 6746-6759. https://doi.org/10.1111/jcmm.16678</mixed-citation></ref><ref id="scirp.121441-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">Liu, Z.Y., Wu, G.P., Lin, Y.Y., et al. (2022) Correlation between Microrna-328 and Atrial Remodeling in Patients with Atrial Fibrillation. Journal of China Medical University, 1-5.</mixed-citation></ref><ref id="scirp.121441-ref19"><label>19</label><mixed-citation publication-type="other" xlink:type="simple">Sethi, N.J., Nielsen, E.E., Safi, S., et al. (2018) Digoxin for Atrial Fibrillation and Atrial Flutter: A Systematic Review with Meta-Analysis and Trial Sequential Analysis of Randomised Clinical Trials. PLOS ONE, 13, e0193924. https://doi.org/10.1371/journal.pone.0193924</mixed-citation></ref><ref id="scirp.121441-ref20"><label>20</label><mixed-citation publication-type="other" xlink:type="simple">Que, D.D. and Song, X.D. (2021) Role of Atrial Remodeling in Atrial Fibrillation. Journal of Practical Electrocardiology, 30, 404-407.</mixed-citation></ref><ref id="scirp.121441-ref21"><label>21</label><mixed-citation publication-type="other" xlink:type="simple">Leask, A. (2015) Getting to the Heart of the Matter: New Insights into Cardiac Fibrosis. Circulation Research, 116, 1269-1276. https://doi.org/10.1161/CIRCRESAHA.116.305381</mixed-citation></ref><ref id="scirp.121441-ref22"><label>22</label><mixed-citation publication-type="other" xlink:type="simple">Wang, L.X., Xiao, Y., Yuan, Y., et al. (2017) Imatinib Attenuates Cardiac Fibrosis by Inhibiting Platelet-Derived Growth Factor Receptors Activation in Isoproterenol Induced Model. PLOS ONE, 12, e0178619. https://doi.org/10.1371/journal.pone.0178619</mixed-citation></ref><ref id="scirp.121441-ref23"><label>23</label><mixed-citation publication-type="other" xlink:type="simple">Tuuminen, R., Nykanen, A.I., Krebs, R., et al. (2009) PDGF-A, -C, and -D but Not PDGF-B Increase TGF-beta1 and Chronic Rejection in Rat Cardiac Allografts. Arteriosclerosis, Thrombosis, and Vascular Biology, 29, 691-698. https://doi.org/10.1161/ATVBAHA.108.178558</mixed-citation></ref><ref id="scirp.121441-ref24"><label>24</label><mixed-citation publication-type="other" xlink:type="simple">Chung, S.-C., Sofat, R., Acosta-Mena, D., et al. (2021) Atrial Fibrillation Epidemiology, Disparity and Healthcare Contacts: A Population-Wide Study of 5.6 Million Individuals. The Lancet Regional Health—Europe, 7, Article ID: 100157. https://doi.org/10.1016/j.lanepe.2021.100157</mixed-citation></ref><ref id="scirp.121441-ref25"><label>25</label><mixed-citation publication-type="other" xlink:type="simple">Nedios, S. (2021) Screening for Atrial Fibrillation: Does Cardiovascular Disease Reduce the Probability of Detection? International Journal of Cardiology, 339, 54-55. https://doi.org/10.1016/j.ijcard.2021.07.003</mixed-citation></ref><ref id="scirp.121441-ref26"><label>26</label><mixed-citation publication-type="other" xlink:type="simple">Liao, C.-H., Akazawa, H., Tamagawa, M., et al. (2010) Cardiac Mast Cells Cause Atrial Fibrillation through PDGF-A-Mediated Fibrosis in Pressure-Overloaded Mouse Hearts. The Journal of Clinical Investigation, 120, 242-253. https://doi.org/10.1172/JCI39942</mixed-citation></ref><ref id="scirp.121441-ref27"><label>27</label><mixed-citation publication-type="other" xlink:type="simple">Pan, J.Q., Zhang, D.X., Shou, X.L., et al. (2016) Features of Atrial Structure in Patients with Valvular Atrial Fibrillation: A Multicenter Study. Journal of Xi’an Jiaotong University (Medical Sciences), 37, 77-107. (in Chinese)</mixed-citation></ref></ref-list></back></article>